Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy

RA Malik, C Li, W Aziz, JA Olson, A Vohra, KC McHardy, JV Forrester, AJM Boulton, PB Wilson, D Liu, D McLeod, S Kumar

Research output: Contribution to journalArticlepeer-review

Abstract

Diabetic retinopathy is the leading cause of blindness in the industrialized world. Hyperglycaemia induces retinal hypoxia that upregulates a range of vasoactive factors which may lead to macular oedema and/or angiogenesis and hence potentially sight threatening retinopathy. In this study, we have focused on the association of CD 105 and vascular endothelial growth factor (VEGF) with the development and progression of diabetic retinopathy by means of quantifying their expression in the plasma and vitreous of diabetic patients. CD105 levels were quantified in the plasma of 38 type I diabetic patients at various stages of retinopathy and 15 non-diabetic controls. In an additional cohort of 11 patients with advanced proliferative retinopathy and 23 control subjects, CD 105 and VEGF were measured in the vitreous. The values were expressed as median (range) and statistical analysis was carried out using the non-parametric Mann-Whitney U test. Plasma CD105 levels were significantly increased in diabetic patients [1.8 (1.1-2.4) ng/ml] compared with non-diabetic controls [0.7 (0.3-1.8) ng/ml] (p
Original languageEnglish
Pages (from-to)692-697
Number of pages6
JournalJournal of cellular and molecular medicine
Volume9
Issue number3
DOIs
Publication statusPublished - Jul 2005

Keywords

  • Angiogenesis
  • CD105
  • Diabetic retinopathy
  • VEGF

Fingerprint

Dive into the research topics of 'Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy'. Together they form a unique fingerprint.

Cite this